Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype

Brunangelo Falini, Cristina Mecucci, Enrico Tiacci, Myriam Alcalay, Roberto Rosati, Laura Pasqualucci, Roberta La Starza, Daniela Diverio, Emanuela Colombo, Antonella Santucci, Barbara Bigerna, Roberta Pacini, Alessandra Pucciarini, Arcangelo Liso, Marco Vignetti, Paola Fazi, Natalia Meani, Valentina Pettirossi, Giuseppe Saglio, Franco MandelliFrancesco Lo-Coco, Pier Giuseppe Pelicci, Massimo F. Martelli

Research output: Contribution to journalArticle

1177 Citations (Scopus)

Abstract

BACKGROUND: Nucleophosmin (NPM), a nucleocytoplasmic shuttling protein with prominent nucleolar localization, regulates the ARF-p53 tumor-suppressor pathway. Translocations involving the NPM gene cause cytoplasmic dislocation of the NPM protein. METHODS: We used immunohistochemical methods to study the subcellular localization of NPM in bone marrow-biopsy specimens from 591 patients with primary acute myelogenous leukemia (AML). We then correlated the presence of cytoplasmic NPM with clinical and biologic features of the disease. RESULTS: Cytoplasmic NPM was detected in 208 (35.2 percent) of the 591 specimens from patients with primary AML but not in 135 secondary AML specimens or in 980 hematopoietic or extrahematopoietic neoplasms other than AML. It was associated with a wide spectrum of morphologic subtypes of the disease, a normal karyotype, and responsiveness to induction chemotherapy, but not with recurrent genetic abnormalities. There was a high frequency of FLT3 internal tandem duplications and absence of CD34 and CD133 in AML specimens with a normal karyotype and cytoplasmic dislocation of NPM, but not in those in which the protein was restricted to the nucleus. AML specimens with cytoplasmic NPM carried mutations of the NPM gene that were predicted to alter the protein at its C-terminal; this mutant gene caused cytoplasmic localization of NPM in transfected cells. CONCLUSIONS: Cytoplasmic NPM is a characteristic feature of a large subgroup of patients with AML who have a normal karyotype, NPM gene mutations, and responsiveness to induction chemotherapy.

Original languageEnglish
Pages (from-to)254-266
Number of pages13
JournalNew England Journal of Medicine
Volume352
Issue number3
DOIs
Publication statusPublished - Jan 20 2005

Fingerprint

Karyotype
Acute Myeloid Leukemia
Induction Chemotherapy
Genes
nucleophosmin
Proteins
Mutation
Neoplasms
Bone Marrow
Biopsy

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Falini, B., Mecucci, C., Tiacci, E., Alcalay, M., Rosati, R., Pasqualucci, L., ... Martelli, M. F. (2005). Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. New England Journal of Medicine, 352(3), 254-266. https://doi.org/10.1056/NEJMoa041974

Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. / Falini, Brunangelo; Mecucci, Cristina; Tiacci, Enrico; Alcalay, Myriam; Rosati, Roberto; Pasqualucci, Laura; La Starza, Roberta; Diverio, Daniela; Colombo, Emanuela; Santucci, Antonella; Bigerna, Barbara; Pacini, Roberta; Pucciarini, Alessandra; Liso, Arcangelo; Vignetti, Marco; Fazi, Paola; Meani, Natalia; Pettirossi, Valentina; Saglio, Giuseppe; Mandelli, Franco; Lo-Coco, Francesco; Pelicci, Pier Giuseppe; Martelli, Massimo F.

In: New England Journal of Medicine, Vol. 352, No. 3, 20.01.2005, p. 254-266.

Research output: Contribution to journalArticle

Falini, B, Mecucci, C, Tiacci, E, Alcalay, M, Rosati, R, Pasqualucci, L, La Starza, R, Diverio, D, Colombo, E, Santucci, A, Bigerna, B, Pacini, R, Pucciarini, A, Liso, A, Vignetti, M, Fazi, P, Meani, N, Pettirossi, V, Saglio, G, Mandelli, F, Lo-Coco, F, Pelicci, PG & Martelli, MF 2005, 'Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype', New England Journal of Medicine, vol. 352, no. 3, pp. 254-266. https://doi.org/10.1056/NEJMoa041974
Falini, Brunangelo ; Mecucci, Cristina ; Tiacci, Enrico ; Alcalay, Myriam ; Rosati, Roberto ; Pasqualucci, Laura ; La Starza, Roberta ; Diverio, Daniela ; Colombo, Emanuela ; Santucci, Antonella ; Bigerna, Barbara ; Pacini, Roberta ; Pucciarini, Alessandra ; Liso, Arcangelo ; Vignetti, Marco ; Fazi, Paola ; Meani, Natalia ; Pettirossi, Valentina ; Saglio, Giuseppe ; Mandelli, Franco ; Lo-Coco, Francesco ; Pelicci, Pier Giuseppe ; Martelli, Massimo F. / Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. In: New England Journal of Medicine. 2005 ; Vol. 352, No. 3. pp. 254-266.
@article{7b260298c9644bdc845122ed89ca2053,
title = "Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype",
abstract = "BACKGROUND: Nucleophosmin (NPM), a nucleocytoplasmic shuttling protein with prominent nucleolar localization, regulates the ARF-p53 tumor-suppressor pathway. Translocations involving the NPM gene cause cytoplasmic dislocation of the NPM protein. METHODS: We used immunohistochemical methods to study the subcellular localization of NPM in bone marrow-biopsy specimens from 591 patients with primary acute myelogenous leukemia (AML). We then correlated the presence of cytoplasmic NPM with clinical and biologic features of the disease. RESULTS: Cytoplasmic NPM was detected in 208 (35.2 percent) of the 591 specimens from patients with primary AML but not in 135 secondary AML specimens or in 980 hematopoietic or extrahematopoietic neoplasms other than AML. It was associated with a wide spectrum of morphologic subtypes of the disease, a normal karyotype, and responsiveness to induction chemotherapy, but not with recurrent genetic abnormalities. There was a high frequency of FLT3 internal tandem duplications and absence of CD34 and CD133 in AML specimens with a normal karyotype and cytoplasmic dislocation of NPM, but not in those in which the protein was restricted to the nucleus. AML specimens with cytoplasmic NPM carried mutations of the NPM gene that were predicted to alter the protein at its C-terminal; this mutant gene caused cytoplasmic localization of NPM in transfected cells. CONCLUSIONS: Cytoplasmic NPM is a characteristic feature of a large subgroup of patients with AML who have a normal karyotype, NPM gene mutations, and responsiveness to induction chemotherapy.",
author = "Brunangelo Falini and Cristina Mecucci and Enrico Tiacci and Myriam Alcalay and Roberto Rosati and Laura Pasqualucci and {La Starza}, Roberta and Daniela Diverio and Emanuela Colombo and Antonella Santucci and Barbara Bigerna and Roberta Pacini and Alessandra Pucciarini and Arcangelo Liso and Marco Vignetti and Paola Fazi and Natalia Meani and Valentina Pettirossi and Giuseppe Saglio and Franco Mandelli and Francesco Lo-Coco and Pelicci, {Pier Giuseppe} and Martelli, {Massimo F.}",
year = "2005",
month = "1",
day = "20",
doi = "10.1056/NEJMoa041974",
language = "English",
volume = "352",
pages = "254--266",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "3",

}

TY - JOUR

T1 - Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype

AU - Falini, Brunangelo

AU - Mecucci, Cristina

AU - Tiacci, Enrico

AU - Alcalay, Myriam

AU - Rosati, Roberto

AU - Pasqualucci, Laura

AU - La Starza, Roberta

AU - Diverio, Daniela

AU - Colombo, Emanuela

AU - Santucci, Antonella

AU - Bigerna, Barbara

AU - Pacini, Roberta

AU - Pucciarini, Alessandra

AU - Liso, Arcangelo

AU - Vignetti, Marco

AU - Fazi, Paola

AU - Meani, Natalia

AU - Pettirossi, Valentina

AU - Saglio, Giuseppe

AU - Mandelli, Franco

AU - Lo-Coco, Francesco

AU - Pelicci, Pier Giuseppe

AU - Martelli, Massimo F.

PY - 2005/1/20

Y1 - 2005/1/20

N2 - BACKGROUND: Nucleophosmin (NPM), a nucleocytoplasmic shuttling protein with prominent nucleolar localization, regulates the ARF-p53 tumor-suppressor pathway. Translocations involving the NPM gene cause cytoplasmic dislocation of the NPM protein. METHODS: We used immunohistochemical methods to study the subcellular localization of NPM in bone marrow-biopsy specimens from 591 patients with primary acute myelogenous leukemia (AML). We then correlated the presence of cytoplasmic NPM with clinical and biologic features of the disease. RESULTS: Cytoplasmic NPM was detected in 208 (35.2 percent) of the 591 specimens from patients with primary AML but not in 135 secondary AML specimens or in 980 hematopoietic or extrahematopoietic neoplasms other than AML. It was associated with a wide spectrum of morphologic subtypes of the disease, a normal karyotype, and responsiveness to induction chemotherapy, but not with recurrent genetic abnormalities. There was a high frequency of FLT3 internal tandem duplications and absence of CD34 and CD133 in AML specimens with a normal karyotype and cytoplasmic dislocation of NPM, but not in those in which the protein was restricted to the nucleus. AML specimens with cytoplasmic NPM carried mutations of the NPM gene that were predicted to alter the protein at its C-terminal; this mutant gene caused cytoplasmic localization of NPM in transfected cells. CONCLUSIONS: Cytoplasmic NPM is a characteristic feature of a large subgroup of patients with AML who have a normal karyotype, NPM gene mutations, and responsiveness to induction chemotherapy.

AB - BACKGROUND: Nucleophosmin (NPM), a nucleocytoplasmic shuttling protein with prominent nucleolar localization, regulates the ARF-p53 tumor-suppressor pathway. Translocations involving the NPM gene cause cytoplasmic dislocation of the NPM protein. METHODS: We used immunohistochemical methods to study the subcellular localization of NPM in bone marrow-biopsy specimens from 591 patients with primary acute myelogenous leukemia (AML). We then correlated the presence of cytoplasmic NPM with clinical and biologic features of the disease. RESULTS: Cytoplasmic NPM was detected in 208 (35.2 percent) of the 591 specimens from patients with primary AML but not in 135 secondary AML specimens or in 980 hematopoietic or extrahematopoietic neoplasms other than AML. It was associated with a wide spectrum of morphologic subtypes of the disease, a normal karyotype, and responsiveness to induction chemotherapy, but not with recurrent genetic abnormalities. There was a high frequency of FLT3 internal tandem duplications and absence of CD34 and CD133 in AML specimens with a normal karyotype and cytoplasmic dislocation of NPM, but not in those in which the protein was restricted to the nucleus. AML specimens with cytoplasmic NPM carried mutations of the NPM gene that were predicted to alter the protein at its C-terminal; this mutant gene caused cytoplasmic localization of NPM in transfected cells. CONCLUSIONS: Cytoplasmic NPM is a characteristic feature of a large subgroup of patients with AML who have a normal karyotype, NPM gene mutations, and responsiveness to induction chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=19944427850&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=19944427850&partnerID=8YFLogxK

U2 - 10.1056/NEJMoa041974

DO - 10.1056/NEJMoa041974

M3 - Article

C2 - 15659725

AN - SCOPUS:19944427850

VL - 352

SP - 254

EP - 266

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 3

ER -